Cigarette smoking, body mass index, gastro-esophageal reflux disease, and non-steroidal anti-inflammatory drug use and risk of subtypes of esophageal and gastric cancers by P53 overexpression

Cancer Causes and Control

Volumn 20, Issue 3, 2009, Pages 361-368

  Figueroa, Jonine D ^a   Terry, Mary Beth ^b   Gammon, Marilie D ^c   Vaughan, Thomas L ^d,e   Risch, Harvey A ^f   Zhang, Fang Fang ^b   Kleiner, David E ^a   Bennett, William P ^g   Howe, Christine L ^f   Dubrow, Robert ^f   Mayne, Susan T ^f   Fraumeni Jr , Joseph F ^a   Chow, Wong Ho ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Columbia University ^*  (United States)

^c IL   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e UNIVERSITY OF WASHINGTON   (United States)

^f YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Body mass index; Esophageal cancer; GERD; NSAIDs; P53; Tobacco

Indexed keywords

ACETYLSALICYLIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN P53;

ADULT; AGED; ARTICLE; BODY MASS; CANCER RISK; CANCER TISSUE; CARDIA CARCINOMA; CIGARETTE SMOKING; CONTROLLED STUDY; DRUG USE; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; FEMALE; GASTROESOPHAGEAL REFLUX; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH ADENOCARCINOMA;

ADENOCARCINOMA; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BODY MASS INDEX; CARCINOMA, SQUAMOUS CELL; CARDIA; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; ESOPHAGEAL NEOPLASMS; GASTROESOPHAGEAL REFLUX; HUMANS; IMMUNOHISTOCHEMISTRY; LOGISTIC MODELS; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; ODDS RATIO; POPULATION SURVEILLANCE; RISK FACTORS; SMOKING; STOMACH NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53; UNITED STATES;

EID: 61449195138     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-008-9250-6     Document Type: Article

References (35)

1. AJ Levine J Momand CA Finlay 1991 The p53 tumour suppressor gene Nature 351 6326 453 456 10.1038/351453a0
2. SP Dowell PO Wilson NW Derias DP Lane PA Hall 1994 Clinical utility of the immunocytochemical detection of p53 protein in cytological specimens Cancer Res 54 11 2914 2918
3. WP Bennett SP Hussain KH Vahakangas MA Khan PG Shields CC Harris 1999 Molecular epidemiology of human cancer risk: gene-environment interactions and p53 mutation spectrum in human lung cancer J Pathol 187 1 8 18 10.1002/(SICI)1096-9896(199901)187:1<8::AID-PATH232>3.0.CO;2-Y
4. M Olivier R Eeles M Hollstein MA Khan CC Harris P Hainaut 2002 The IARC TP53 database: new online mutation analysis and recommendations to users Hum Mutat 19 6 607 614 10.1002/humu.10081
5. T Soussi C Beroud 2001 Assessing TP53 status in human tumours to evaluate clinical outcome Nat Rev Cancer 1 3 233 240 10.1038/35106009
6. MD Gammon MB Terry N Arber WH Chow HA Risch TL Vaughan 2004 Nonsteroidal anti-inflammatory drug use associated with reduced incidence of adenocarcinomas of the esophagus and gastric cardia that overexpress cyclin D1: a population-based study Cancer Epidemiol Biomarkers Prev 13 1 34 39 10.1158/1055-9965.EPI-03-0198
7. G Coggi S Bosari M Roncalli D Graziani P Bossi G Viale 1997 p53 protein accumulation and p53 gene mutation in esophageal carcinoma. A molecular and immunohistochemical study with clinicopathologic correlations Cancer 79 3 425 432 10.1002/(SICI)1097-0142(19970201)79:3<425::AID-CNCR1>3.0.CO;2-H
8. SH Doak GJ Jenkins EM Parry AP Griffiths V Shah JN Baxter 2003 Characterisation of p53 status at the gene, chromosomal and protein levels in oesophageal adenocarcinoma Br J Cancer 89 9 1729 1735 10.1038/sj.bjc.6601323
9. JF Flejou F Muzeau F Potet F Lepelletier F Fekete D Henin 1994 Overexpression of the p53 tumor suppressor gene product in esophageal and gastric carcinomas Pathol Res Pract 190 12 1141 1148
10. CM Gleeson JM Sloan DT McManus P Maxwell K Arthur JA McGuigan 1998 Comparison of p53 and DNA content abnormalities in adenocarcinoma of the oesophagus and gastric cardia Br J Cancer 77 2 277 286
11. I Jovanovic V Todorovic T Milosavljevic M Micev P Pesko M Bjelovic 2005 Expression of p53 protein in Barrett's adenocarcinoma and adenocarcinoma of the gastric cardia and antrum Vojnosanit Pregl 62 12 879 885
12. ST Shi GY Yang LD Wang Z Xue B Feng W Ding 1999 Role of p53 gene mutations in human esophageal carcinogenesis: results from immunohistochemical and mutation analyses of carcinomas and nearby non-cancerous lesions Carcinogenesis 20 4 591 597 10.1093/carcin/20.4.591
13. H Ahsan AI Neugut MD Gammon 1997 Association of adenocarcinoma and squamous cell carcinoma of the esophagus with tobacco-related and other malignancies Cancer Epidemiol Biomarkers Prev 6 10 779 782
14. MD Gammon JB Schoenberg H Ahsan HA Risch TL Vaughan WH Chow 1997 Tobacco, alcohol, and socioeconomic status and adenocarcinomas of the esophagus and gastric cardia J Natl Cancer Inst 89 17 1277 1284 10.1093/jnci/89.17.1277
15. M Lindblad LA Rodriguez J Lagergren 2005 Body mass, tobacco and alcohol and risk of esophageal, gastric cardia, and gastric non-cardia adenocarcinoma among men and women in a nested case-control study Cancer Causes Control 16 3 285 294 10.1007/s10552-004-3485-7
16. DA Corley K Kerlikowske R Verma P Buffler 2003 Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis Gastroenterology 124 1 47 56 10.1053/gast.2003.50008
17. DC Farrow TL Vaughan PD Hansten JL Stanford HA Risch MD Gammon 1998 Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer Cancer Epidemiol Biomarkers Prev 7 2 97 102
18. WH Chow WJ Blot TL Vaughan HA Risch MD Gammon JL Stanford 1998 Body mass index and risk of adenocarcinomas of the esophagus and gastric cardia J Natl Cancer Inst 90 2 150 155 10.1093/jnci/90.2.150
19. J Lagergren R Bergstrom O Nyren 1999 Association between body mass and adenocarcinoma of the esophagus and gastric cardia Ann Intern Med 130 11 883 890
20. DC Farrow TL Vaughan C Sweeney MD Gammon WH Chow HA Risch 2000 Gastroesophageal reflux disease, use of H2 receptor antagonists, and risk of esophageal and gastric cancer Cancer Causes Control 11 3 231 238 10.1023/A:1008913828105
21. H Hampel NS Abraham HB El-Serag 2005 Meta-analysis: obesity and the risk for gastroesophageal reflux disease and its complications Ann Intern Med 143 3 199 211
22. Wakesberg J (1978) Sampling methods for random digit dialing. J Am Stat Assoc (73):40-46. doi: 10.2307/2286513
23. DG Guinee Jr WD Travis GE Trivers VM De Benedetti H Cawley JA Welsh 1995 Gender comparisons in human lung cancer: analysis of p53 mutations, anti-p53 serum antibodies and C-erbB-2 expression Carcinogenesis 16 5 993 1002 10.1093/carcin/16.5.993
24. SR Shi ME Key KL Kalra 1991 Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections J Histochem Cytochem 39 6 741 748
25. SM Hsu L Raine H Fanger 1981 Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures J Histochem Cytochem 29 4 577 580
26. Hosmer DW, Lemeshow S (1989) Applied logistic regression. Wiley, New York
27. KD Crew AI Neugut 2004 Epidemiology of upper gastrointestinal malignancies Semin Oncol 31 4 450 464 10.1053/j.seminoncol.2004.04.021
28. H Saeki S Ohno M Miyazaki K Araki A Egashira H Kawaguchi 2002 p53 protein accumulation in multiple oesophageal squamous cell carcinoma: relationship to risk factors Oncology 62 2 175 179 10.1159/000048264
29. R Montesano M Hollstein P Hainaut 1996 Genetic alterations in esophageal cancer and their relevance to etiology and pathogenesis: a review Int J Cancer 69 3 225 235 10.1002/(SICI)1097-0215(19960621)69:3<225::AID-IJC13>3.0. CO;2-6
30. TL Vaughan AR Kristal PL Blount DS Levine PC Galipeau LJ Prevo 2002 Nonsteroidal anti-inflammatory drug use, body mass index, and anthropometry in relation to genetic and flow cytometric abnormalities in Barrett's esophagus Cancer Epidemiol Biomarkers Prev 11 8 745 752
31. D Palli NE Caporaso YH Shiao C Saieva A Amorosi G Masala 1997 Diet, Helicobacter pylori, and p53 mutations in gastric cancer: a molecular epidemiology study in Italy Cancer Epidemiol Biomarkers Prev 6 12 1065 1069
32. J Theisen JH Peters M Fein M Hughes JA Hagen SR Demeester 2005 The mutagenic potential of duodenoesophageal reflux Ann Surg 241 1 63 68
33. YS Bian MC Osterheld FT Bosman J Benhattar C Fontolliet 2001 p53 gene mutation and protein accumulation during neoplastic progression in Barrett's esophagus Mod Pathol 14 5 397 403 10.1038/modpathol.3880324
34. DT McManus A Olaru SJ Meltzer 2004 Biomarkers of esophageal adenocarcinoma and Barrett's esophagus Cancer Res 64 5 1561 1569 10.1158/0008-5472.CAN-03-2438
35. KF Trivers AJ De Roos MD Gammon TL Vaughan HA Risch AF Olshan 2005 Demographic and lifestyle predictors of survival in patients with esophageal or gastric cancers Clin Gastroenterol Hepatol 3 3 225 230 10.1016/S1542-3565(04) 00613-5